Leerink Global Healthcare Conference 2026
Logotype for 908 Devices Inc

908 Devices (MASS) Leerink Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for 908 Devices Inc

Leerink Global Healthcare Conference 2026 summary

9 Mar, 2026

Market drivers and macro environment

  • Demand is driven by illicit drug crises, toxic industrial chemicals, and global unrest, with conflicts like Ukraine and Middle East tensions increasing customer prioritization for modernization and preparedness.

  • NATO countries are increasing defense spending targets to 5% of GDP by 2035, supporting a rising tide in customer demand.

  • International revenues grew from 25% to 27% of total, with ambitions to reach 40-50% as global demand rises.

  • No immediate impact from inflation or oil prices, as most funding is grant-based and already allocated.

  • U.S. government funding remains robust, with 11 of 12 appropriations bills passed and multi-year grants supporting state and local customers.

Financial performance and outlook

  • Achieved 21% revenue growth in Q4, surpassing guidance, with state and local customers contributing 43% of annual revenue.

  • Guidance for 2026 targets 15-20% annual growth, with Q1 expected to be slower due to product restocking and typical seasonality.

  • Adjusted EBITDA turned positive in Q4 ($700K), with a path to full-year profitability by 2027 as growth and margin improvements continue.

  • Gross margin expected to expand by 100 basis points, driven by insourcing, Danbury consolidation, and product mix.

  • Recurring revenue rose 22% year-over-year, now 35% of total, with further growth expected from software and OEM channels.

Product innovation and pipeline

  • Next-gen MX908 handheld mass spectrometer to be announced later this year, targeting both replacement and expansion opportunities.

  • VipIR and XplorIR products showed strong traction, with over 40 and 150 installs respectively, and are expected to drive growth in new and existing accounts.

  • AVCAD OEM program with Smiths Detection expected to ramp from $2-3 million in 2026 to potentially $10 million annually over 5-7 years.

  • Product development focuses on reducing size, weight, and complexity, responding to customer feedback for simplicity and ease of use.

  • Team Leader software and expanded portfolio aim to increase recurring revenue and market penetration.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more